-
PARIS Conference leaders initiated a new feature at the 14th European Paris Course on Revascularization (EuroPCR), held here in late May. Ten emerging companies were selected from among many contenders based on the innovative nature of their cardiovascular technologies and the clinical solutions they provide.
-
Abbott Laboratories (Abbott Park, Illinois) entered into an asset purchase agreement for the coronary and peripheral interventional business line of the Jomed Group, a provider of minimally invasive vascular interventional devices, for EUR 60 million.
-
Boston Scientific (Natick, Massachusetts) reported June 20 that the U.S. Court of Appeals for the Seventh Circuit had substantially affirmed a U.S. District Court decision in favor of the company in its dispute with Cook (Bloomington, Indiana) over Cooks agreements with Guidant (Indianapolis, Indiana) relating to paclitaxel-coated stents.
-
A decision made last month by the Centers for Medicare & Medicaid Services (CMS; Baltimore, Maryland) means another 90,000 patients a year will qualify for reimbursement coverage to receive implantable cardioverter defibrillators (ICDs), but the coverage guidelines fall short for another 200,000 people researchers say would benefit from the devices.
-
Timothy Moore, MD, has been named chief medical officer and executive vice president for Alere Medical (Reno, Nevada). Moore most recently was chief medical officer and senior vice president of Health Net.
-
A second company earned U.S. regulatory approval in the embolic protection field last month, with Boston Scientifics (Natick, Massachusetts) FilterWire EX Embolic Protection System joining Medtronics (Minneapolis, Minnesota) PercuSurge GuardWire Plus system, which was approved by the FDA in June 2001.
-
-
BOSTON, Massachusetts The 83rd annual meeting of the American Association for Thoracic Surgery (AATS; Beverly, Massachusetts) provided one of the first forums for cardiac surgeons to discuss the future impact of the new drug-eluting coronary stents on patient management.
-
Advances in Cardiovascular Technology: Emerging Markets for the 21st Century, a sourcebook produced by the BBI group of Thomson BioWorld, publishers of Cardiovascular Device Update, received second-place honors in the Best Looseleaf Publication category of awards issued for 2002 by the Newsletter and Electronic Publishers Association, the major organization representing the worldwide newsletter industry.
-
According to the Carvedilol or Metoprolol European Trial (COMET), chronic heart failure (CHF) patients treated with the beta blocking agent carvedilol had a significant survival benefit 17% better than those taking the selective beta blocker metoprolol.
